Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
Marker Therapeutics today announced it has treated the first patient in the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate. The trial is enrolling patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings.